<DOC>
	<DOCNO>NCT01183455</DOCNO>
	<brief_summary>Aralast NP ( alpha-1 antitrypsin , AAT ) , alpha-1 proteinase inhibitor ( human ) , drug test clinical trial . Aralast NP anti-inflammatory drug affect cell thought involve development type 1 diabetes mellitus ( T1DM , T1D ) . This study , know RETAIN , plan two-part trial investigate effect Aralast NP preserve beta cell function determine intervention would slow progression type 1 diabetes . Part I trial ( NCT 01183468 ) open-label , safety dose level study consist two group . After completion Part I , include satisfactory safety review , enrollment Part II begin . Part II design two-arm , double-blind , placebo-controlled clinical trial , participant randomly assign either Aralast NP treatment placebo group .</brief_summary>
	<brief_title>A Research Trial Aralast NP New Onset Diabetes ( RETAIN ) - Part II</brief_title>
	<detailed_description>T1D autoimmune disease . This mean immune system ( part body help fight infection ) mistakenly attack cell produce insulin ( beta cell pancreas ) . As beta cell destroy immune cell , ability produce insulin decrease . Insulin help keep blood glucose level normal . Individuals T1D ability produce insulin ( even though still need take insulin ) may able achieve good glucose control people produce insulin . Better glucose control show reduce long-term complication diabetes . Previous research show give medicine affect immune system soon type 1 diabetes diagnose may stop , delay decrease destruction beta cell , result good glucose control . In mouse model disease , alpha-1 proteinase inhibitor show reverse new-onset diabetes induce state self-tolerance . The RETAIN clinical trial intend investigate effect Aralast NP preserve beta cell function slow progression T1D .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Diagnosed type 1 diabetes ( T1D ) within past 100 day Positive least one diabetesrelated autoantibody ( antiGAD ; antiinsulin , obtain within 10 day onset insulin therapy ; IA2 antibody and/or ICA , ZnT8 ) Peak stimulate Cpeptide level great ( &gt; ) 0.2 pmol/mL follow mixed meal tolerance test ( MMTT ) Severe active disease ( hepatitis , cardiac pulmonary disease , hypertension , immunodeficiency ) History bleed clot factor deficiency , stroke History vascular disease significant vascular abnormality Positive serology exposure hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) toxoplasmosis Clinically active infection EpsteinBarr virus ( EBV ) , cytomegalovirus ( CMV ) , tuberculosis ( TB ) Prior current use oral , inhaled intranasal glucocorticoid , medication know cause significant , ongoing change course T1D immunologic status Prior treatment alpha1antitrypsin ( AAT ) hypersensitivity AAT human plasmaderived product Current prior ( within last 30 day ) use metformin , sulfonylurea , glinides , thiazolidinediones , exenatide , liraglutide , DPPIV inhibitor amylin Current use medication know influence glucose tolerance ( e.g. , betablockers , angiotensinconverting enzyme inhibitor , interferon , quinidine antimalarial drug , lithium , niacin ) Females pregnant lactating , unwilling defer pregnancy study participation Immunoglobulin A ( IgA ) deficiency Uncontrolled hypertension Current lifethreatening malignancy Any condition investigator 's opinion may compromise study participation may confound interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Diabetes Mellitus , Type 1 ( new-onset )</keyword>
	<keyword>T1DM ( new-onset )</keyword>
	<keyword>T1D ( new-onset )</keyword>
	<keyword>Diabetes , Autoimmune</keyword>
	<keyword>Alpha1-Proteinase Inhibitor</keyword>
	<keyword>Alpha-1 Antitrypsin</keyword>
	<keyword>AAT</keyword>
</DOC>